GARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational ...

Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19thGARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- ...

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, ...

Beyond Air Inc (NASDAQ:XAIR) is among the best NASDAQ penny stocks to buy according to analysts. On February 20, Beyond Air Inc (NASDAQ:XAIR) commented that it was pleased with a review article that ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The consensus fair value ...

Beyond Air, Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, expectations were $-0.45. Operator: Good morning, and welcome, everyone, to Beyond Air Financial Results Call for the ...

Steven Adam Lisi, Chief Executive Officer of Beyond Air, Inc. Steve, go ahead. Thanks, Corey. And good morning to everyone. With me here today is Dan Moorhead, our new Chief Financial Officer. It has ...

Beyond Air missed estimated earnings by -14.86%, reporting an EPS of $-0.85 versus an estimate of $-0.74. Revenue was up $1.12 million from the same period last year. Last quarter the company missed ...

Image source: The Motley Fool. Beyond Air (NASDAQ:XAIR) delivered triple-digit revenue growth and sequential improvement in gross profit, citing significant traction for its LungFit PH platform.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Beyond Air stock surged 150% as XTL Biopharmaceuticals acquired 85% of NeuroNOS subsidiary for up to $32.5M in cash and milestones. Trading volume jumped 363%. XTL Biopharmaceuticals agreed to acquire ...